m6A Target Gene Information
General Information of the m6A Target Gene (ID: M6ATAR00537)
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
MAP2K4
can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
YTH domain-containing family protein 2 (YTHDF2) [READER]
Representative RIP-seq result supporting the interaction between MAP2K4 and the regulator | ||
Cell Line | Hela | Homo sapiens |
Regulation | logFC: 2.75E+00 | GSE49339 |
In total 2 item(s) under this regulator | ||||
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene | [1] | |||
Response Summary | YTHDF2 regulates the stability of MAP kinase kinase 4 (MAP2K4) and MAP4K4 mRNAs.This study identified that dasatinib and quercetin alleviate LPS-induced senescence in HUVECs via the TRAF6-MAPK-NF-Kappa-B axis in a YTHDF2-dependent manner, providing novel ideas for clinical treatment of age-related cardiovascular diseases. | |||
Responsed Disease | Diseases of the circulatory system | ICD-11: BE2Z | ||
Experiment 2 Reporting the m6A Methylation Regulator of This Target Gene | [2] | |||
Response Summary | YTHDF2 knockdown increases mRNA expression levels of MAP kinase kinase 4 (MAP2K4) and MAP4K4 via stabilizing the mRNA transcripts, which activate MAPK and NF-Kappa-B signaling pathways, which promote the expression of proinflammatory cytokines and aggravate the inflammatory response in LPS-stimulated RAW 264.7 cells. | |||
Target Regulation | Down regulation | |||
Responsed Disease | Inflammatory response | ICD-11: MG46 | ||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
In-vitro Model | RAW 264.7 | Mouse leukemia | Mus musculus | CVCL_0493 |
Diseases of the circulatory system [ICD-11: BE2Z]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [1] | |||
Response Summary | YTHDF2 regulates the stability of MAP kinase kinase 4 (MAP2K4) and MAP4K4 mRNAs.This study identified that dasatinib and quercetin alleviate LPS-induced senescence in HUVECs via the TRAF6-MAPK-NF-Kappa-B axis in a YTHDF2-dependent manner, providing novel ideas for clinical treatment of age-related cardiovascular diseases. | |||
Responsed Disease | Diseases of the circulatory system [ICD-11: BE2Z] | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Inflammatory response [ICD-11: MG46]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the m6A-centered Disease Response | [2] | |||
Response Summary | YTHDF2 knockdown increases mRNA expression levels of MAP kinase kinase 4 (MAP2K4) and MAP4K4 via stabilizing the mRNA transcripts, which activate MAPK and NF-Kappa-B signaling pathways, which promote the expression of proinflammatory cytokines and aggravate the inflammatory response in LPS-stimulated RAW 264.7 cells. | |||
Responsed Disease | Inflammatory response [ICD-11: MG46] | |||
Target Regulator | YTH domain-containing family protein 2 (YTHDF2) | READER | ||
Target Regulation | Down regulation | |||
Pathway Response | MAPK signaling pathway | hsa04010 | ||
In-vitro Model | RAW 264.7 | Mouse leukemia | Mus musculus | CVCL_0493 |
References